Did you know that dysregulation of the immune system’s precise balance can lead to serious health conditions, like #autoimmune diseases and cancer? Cullinan’s unique scientific approach aims to restore immune balance by targeting and harnessing key mechanisms of immune modulation.? ? Watch and learn more: https://bit.ly/40dEUlZ?
Cullinan Therapeutics
生物技术研究
Cambridge，Massachusetts 9,192 位关注者
Modality-Agnostic Targeted Therapeutics
关于我们
Cullinan Therapeutics is dedicated to creating new standards of care for patients. We have strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Our portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of cancer and autoimmune indications. Notice to Job Seekers: Job applicants should be aware of job recruitment, interview and offer scams being perpetrated through the use of the internet and social media platforms. To learn more, visit our Careers page or read Cullinan’s Employment Recruitment Scams Notice here: https://cullinantherapeutics.com/docs/employment-recruitment-scams-notice.pdf
- 网站
-
https://www.cullinantherapeutics.com
Cullinan Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Cambridge，Massachusetts
- 类型
- 上市公司
- 领域
- Oncology和Auto-Immune Diseases
地点
-
主要
获取路线
1 Main St
US，Massachusetts，Cambridge，02142
Cullinan Therapeutics员工
动态
-
Our Q4 and full year 2024 financial results, announced today, highlight our position to deliver meaningful catalysts and new clinical data in 2025. We continue to progress our diversified pipeline in #autoimmune diseases and #cancer. Learn more: https://bit.ly/41xa89y
-
-
As #BlackHistoryMonth comes to a close, we are proud to share we have made a contribution to local nonprofit Young Man With a Plan (YMWAP) to create hygiene kits with culturally appropriate products for the young men in their program. YMWAP delivers a program of holistic mentoring that helps Black and Latino men in Boston build brotherhood, make academic and social emotional gains, and access sustainable futures to help them achieve college, career, and life success. Learn more here: https://lnkd.in/dghPp6CU
-
-
On the International Day of Women and Girls in Science, we celebrate the daily achievements of #WomenInScience who consistently challenge the status quo.? ? Cullinan is proud to have amazing women throughout our organization, pushing the boundaries of science to build a brighter future for all.? ? Hear from Judy Inumerable, Cullinan’s Senior Director, Clinical Development, about the importance of diverse representation in clinical development.?? ? Learn more about our commitment to DEI: https://bit.ly/3WgYyfv
-
Today at 9:30 a.m. ET, Nadim Ahmed, President and CEO, and Jeff Jones, MD, MBA, Chief Medical Officer, will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference. Watch the recording here: https://bit.ly/3WMmOqk
-
-
#WorldCancerDay brings the global cancer community together to place people at the center of care.? ? At Cullinan, patients’ needs drive our relentless pursuit of groundbreaking science to create new standards of care across a wide variety of cancers.? ? #UnitedbyUnique
-
-
On #RheumatoidArthritisAwarenessDay, we are committed to increasing awareness, fostering understanding, and advancing healthcare equity for the 18 million people worldwide living with the condition.? ? We are working to offer patients more effective, durable treatment options by exploring T cell engagers for the management of #autoimmune diseases like RA.? ? Learn more: https://bit.ly/4a9u593?
-
-
Our focus has and always will be creating new standards of care for patients. Jeff Jones, our Chief Medical Officer, discusses how we prioritize programs that will make a positive difference in patients’ lives. https://bit.ly/3Wdo5Xb
-
Today, we announced the Phase 2b REZILIENT1 trial of zipalertinib in patients with non-small cell lung cancer (#NSCLC) met its primary endpoint of overall response rate. Learn more here: https://bit.ly/3Cu39V0 ?? Zipalertinib is being developed in partnership with Taiho Pharmaceutical and Taiho Oncology, Inc.
-
-
#Biotech sits at an exciting crossroads. As we learn more about the shared mechanisms of oncology and immunology, we have an unprecedented opportunity to reimagine how we address unmet patient needs.? ? In his new MedCity News article, Nadim Ahmed, President and CEO, shares his perspective on how leading with a commitment to boldness, agility, and thoughtfulness is necessary to accelerate innovation.??? ? Read his full article here: https://bit.ly/4avDyYh?
-